INDV
Indivior Pharmaceuticals, Inc.
Key Financials
Operating Income
$262.0M
↑ 718.8%
Revenue
$1.2B
↑ 4.3%
Gross Profit
$994.0M
↑ 3.9%
Net Income
$210.0M
↑ 10400.0%
EPS (Diluted)
$1.64
↑ 8100.0%
Total Liabilities
$1.3B
↓ 22.1%
Total Assets
$1.2B
↓ 8.9%
Cash & Equivalents
$195.0M
↓ 38.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 144 | 6/11/2026 | View on SEC |
| 4 | 6/10/2026 | View on SEC |
| 144/A | 6/8/2026 | View on SEC |
| 144 | 6/8/2026 | View on SEC |
| 8-K | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 4 | 5/14/2026 | View on SEC |
| 4 | 5/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | INDV |
| Company Name | Indivior Pharmaceuticals, Inc. |
| CIK | 1625297 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 804-379-1090 |